Iradimed Co
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories, and disposables and services in the United States and internationally. The company offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; MRI compatible patient vital signs monitoring syst… Read more
Iradimed Co (IRMD) - Total Assets
Latest total assets as of December 2025: $108.78 Million USD
Based on the latest financial reports, Iradimed Co (IRMD) holds total assets worth $108.78 Million USD as of December 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Iradimed Co - Total Assets Trend (2012–2025)
This chart illustrates how Iradimed Co’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Iradimed Co - Asset Composition Analysis
Current Asset Composition (December 2025)
Iradimed Co's total assets of $108.78 Million consist of 74.7% current assets and 25.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 47.0% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $3.38 Million | 3.1% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2012–2025)
This chart illustrates how Iradimed Co's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Iradimed Co's current assets represent 74.7% of total assets in 2025, a decrease from 90.0% in 2012.
- Cash Position: Cash and equivalents constituted 47.0% of total assets in 2025, up from 30.6% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, a decrease from 4.0% in 2012.
- Asset Diversification: The largest asset category is intangible assets at 3.1% of total assets.
Iradimed Co Competitors by Total Assets
Key competitors of Iradimed Co based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022
|
China | CN¥5.17 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.67 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥4.55 Billion |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932
|
China | CN¥6.10 Billion |
|
Shinhung
KO:004080
|
Korea | ₩153.50 Billion |
|
UMediC Group Berhad
KLSE:0256
|
Malaysia | RM94.93 Million |
|
Osang Healthcare Co.,Ltd
KQ:036220
|
Korea | ₩287.70 Billion |
|
HansBiomed Corporation
KQ:042520
|
Korea | ₩126.41 Billion |
Iradimed Co - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Iradimed Co generates 0.77x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, Iradimed Co generates $ 20.67 in net profit.
Iradimed Co - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.98 | 8.84 | 14.07 |
| Quick Ratio | 7.98 | 7.62 | 13.07 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $71.02 Million | $ 66.73 Million | $ 60.58 Million |
Iradimed Co - Advanced Valuation Insights
This section examines the relationship between Iradimed Co's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 13.25 |
| Latest Market Cap to Assets Ratio | 7.76 |
| Asset Growth Rate (YoY) | 10.6% |
| Total Assets | $108.78 Million |
| Market Capitalization | $843.89 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Iradimed Co's assets at a significant premium ( 7.76x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Iradimed Co's assets grew by 10.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Iradimed Co (2012–2025)
The table below shows the annual total assets of Iradimed Co from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $108.78 Million | +10.63% |
| 2024-12-31 | $98.33 Million | +6.69% |
| 2023-12-31 | $92.16 Million | +7.77% |
| 2022-12-31 | $85.51 Million | +3.18% |
| 2021-12-31 | $82.88 Million | +16.62% |
| 2020-12-31 | $71.07 Million | +6.50% |
| 2019-12-31 | $66.73 Million | +37.75% |
| 2018-12-31 | $48.44 Million | +24.17% |
| 2017-12-31 | $39.01 Million | +4.89% |
| 2016-12-31 | $37.19 Million | +5.53% |
| 2015-12-31 | $35.24 Million | +51.20% |
| 2014-12-31 | $23.31 Million | +233.62% |
| 2013-12-31 | $6.99 Million | +25.79% |
| 2012-12-31 | $5.55 Million | -- |